Cited by 122Ovarian cancer diagnosis and treatmentCancer Cells and MetastasisReproductive Biology and Fertility

The DOI matches its Crossref record; 42 of the 43 references it cites were found in a registry or an index.

Characterization of ovarian cancer cell lines as in vivo models for preclinical studies

Open access

Hernandez, Lidia, Kim, Marianne K., Lyle, L. Tiffany, Bunch, Kristen P., House, Carrie D., Ning, Franklin, Noonan, Anne M., Annunziata, Christina M.·2016·Gynecologic Oncology

DOI 10.1016/j.ygyno.2016.05.028PMC PMC4961516

Open this paper in CoChat — free account

Abstract

Objective The value of cell lines for pre-clinical work lies in choosing those with similar characteristics. Selection of cell lines is typically based on patient history, histological subtype at diagnosis, mutation patterns, or signaling pathways. Although recent studies established consensus regarding molecular characteristics of ovarian cancer cell lines, data on in vivo tumorigenicity remains only sporadically available, impeding translation of in vitro work to xenograft models.Methods We introduced 18 ovarian cancer cell lines into athymic nude mice through subcutaneous, intraperitoneal, and ovary intrabursal routes, and observed tumor development over 6weeks. We also profiled cell line gene expression and identified differentially expressed gene sets based on their ability to form tumors in the subcutaneous or intraperitoneal locations. Representative cell lines were further subjected to proteomic analyses.Results Ovarian cancer cell lines showed variable ability to grow in mice when implanted subcutaneous, intraperitoneal, or intrabursal. While some cell lines grew well in both SC and IP locations, others showed a strong propensity to grow in one location only. Gene expression profiles suggested that cell lines showing preference for IP growth had gene expression patterns more similar to primary tumors.Conclusions We report the tumorigenicity of 17 human ovarian cancer cell lines and one mouse cell line in three distinct anatomical locations, and associated gene networks. Growth patterns and histopathology, linked to molecular characteristics, provide a valuable resource to the research community, and better guide the choice of cell lines for in vitro studies to translate efficiently into xenograft testing.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/j.ygyno.2016.05.028

Cites

42 of 42 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cancer statistics, 2015
Siegel, R. L., Miller, K. D., & Jemal, A. (2015) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21254 · Cited by 11,854
Integrated genomic analyses of ovarian carcinoma
Perou, C. M. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/hvp3-wg08 · Cited by 7,927
Ovarian Cancer Development and Metastasis
Lengyel, E. R. (2010) · American Journal Of Pathology · doi:10.2353/ajpath.2010.100105 · Cited by 1,702
Novel Molecular Subtypes of Serous and Endometrioid Ovarian Cancer Linked to Clinical Outcome
Tothill, R. W., Tinker, A. V., George, J., Brown, R. E., Fox, S. B., Lade, S., Johnson, D., Trivett, M. K., Etemadmoghadam, D., Locandro, B., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0196 · Cited by 1,458
Evaluating cell lines as tumour models by comparison of genomic profiles
Domcke, S., Sinha, R., Levine, D. A., Sander, C., & Schultz, N. D. (2013) · Nature Communications · doi:10.1038/ncomms3126 · Cited by 1,457
Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case-control studies
Pearce, C. L., Templeman, C., Rossing, M. A., Lee, A., Near, A. M., Webb, P. M., Nagle, C. M., Doherty, J. A., Cushing-Haugen, K. L., Wicklund, K. G., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70404-1 · Cited by 939
Absence of HeLa Cell Contamination in 169 Cell Lines Derived From Human Tumors2
Fogh, J., Wright, W. C., & Loveless, J. D. (1977) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/58.2.209 · Cited by 663
Development of a Syngeneic Mouse Model for Events Related to Ovarian Cancer
Roby, K. F., Taylor, C. C., Sweetwood, J. P., Cheng, Y., Pace, J. L., Tawfik, O., Persons, D. L., Smith, P. G., & Terranova, P. F. (2000) · Carcinogenesis · doi:10.1093/carcin/21.4.585 · Cited by 593
Characterization of a human ovarian carcinoma cell line (NIH:OVCAR-3) with androgen and estrogen receptors.
Hamilton, T. C., Young, R. C., McKoy, W. M., Grotzinger, K. R., Green, J. A., Chu, E. W., Whang‐Peng, J., Rogan, A. M., Green, W. R., & Ozols, R. F. (1983) · PubMed · Cited by 539
Characterization of a cis-diamminedichloroplatinum(II)-resistant human ovarian cancer cell line and its use in evaluation of platinum analogues.
Behrens, B. C., Hamilton, T. C., Masuda, H., Grotzinger, K. R., Whang‐Peng, J., Louie, K. G., Knutsen, T., McKoy, W. M., Young, R. C., & Ozols, R. F. (1987) · PubMed · Cited by 498

Show all 43 references

Sorted by citations

Fucoidan Structure and Activity in Relation to Anti-Cancer Mechanisms
van Weelden, G. H., Bobiński, M. S., Okła, K., van Weelden, W. J., Romano, A., & Pijnenborg, J. M. A. (2019) · Marine Drugs · doi:10.3390/md17010032 · Cited by 340
Malignant Ascites in Ovarian Cancer: Cellular, Acellular, and Biophysical Determinants of Molecular Characteristics and Therapy Response
Rickard, B. P., Conrad, C., Sorrin, A. J., Ruhi, M. K., Reader, J. C., Huang, S. A., Franco, W., Scarcelli, G., Polacheck, W. J., Roque, D. M., et al. (2021) · Cancers · doi:10.3390/cancers13174318 · Cited by 163
Ovarian cancer cell lines derived from non-serous carcinomas migrate and invade more aggressively than those derived from high-grade serous carcinomas
Hallas-Potts, A., Dawson, J. C., & Herrington, C. S. (2019) · Scientific Reports · doi:10.1038/s41598-019-41941-4 · Cited by 110
Activation of Wnt signaling promotes olaparib resistant ovarian cancer
Yamamoto, T. M., McMellen, A. N., Watson, Z. L., Aguilera, J., Ferguson, R. L., Nurmemmedov, E., Thakar, T., Moldovan, G., Kim, H., Cittelly, D. M., et al. (2019) · Molecular Carcinogenesis · doi:10.1002/mc.23064 · Cited by 102
NFκB Promotes Ovarian Tumorigenesis via Classical Pathways That Support Proliferative Cancer Cells and Alternative Pathways That Support ALDH+ Cancer Stem–like Cells
House, C. D., Jordan, E., Hernandez, L. F., Ozaki, M. K., James, J. M., Kim, M., Kruhlak, M. J., Batchelor, E., Elloumi, F., Cam, M. C., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-0366 · Cited by 94
Self-citation
Current Status of Patient-Derived Ovarian Cancer Models
Maru, Y., & Hippo, Y. (2019) · Cells · doi:10.3390/cells8050505 · Cited by 92
Characterization of SOX2, OCT4 and NANOG in Ovarian Cancer Tumor-Initiating Cells
Robinson, M., Gilbert, S. F., Waters, J. A., Lujano-Olazaba, O., Lara, J., Alexander, L. J., Green, S. E., Burkeen, G., Patrus, O., Sarwar, Z., et al. (2021) · Cancers · doi:10.3390/cancers13020262 · Cited by 84
Self-citation
Sequential combination of cisplatin with eugenol targets ovarian cancer stem cells through the Notch-Hes1 signalling pathway
Islam, S. S., & Aboussekhra, A. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1360-3 · Cited by 74
Cell type‐selective pathways and clinical associations of lysophosphatidic acid biosynthesis and signaling in the ovarian cancer microenvironment
Reinartz, S., Lieber, S., Pesek, J., Brandt, D. T., Asafova, A., Finkernagel, F., Watzer, B., Nockher, W. A., Nist, A., Stiewe, T., et al. (2018) · Molecular Oncology · doi:10.1002/1878-0261.12396 · Cited by 73
Curcumin Nanoparticle Enhances the Anticancer Effect of Cisplatin by Inhibiting PI3K/AKT and JAK/STAT3 Pathway in Rat Ovarian Carcinoma Induced by DMBA
Sandhiutami, N. M. D., Arozal, W., Louisa, M., Rahmat, D., & Wuyung, P. E. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.603235 · Cited by 73
Three-dimensional modelling of ovarian cancer: from cell lines to organoids for discovery and personalized medicine
Yee, C., Dickson, K.-A., Muntasir, M. N., Ma, Y., & Marsh, D. J. (2022) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2022.836984 · Cited by 66
Drug resistance evaluation in novel 3D in vitro model
Nowacka, M., Sterzyńska, K., Andrzejewska, M., Nowicki, M. O., & Januchowski, R. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111536 · Cited by 64
Autophagy gene haploinsufficiency drives chromosome instability, increases migration, and promotes early ovarian tumors
Delaney, J. R., Patel, C. B., Bapat, J., Jones, C. M., Zapatero, M. R., Ortell, K. K., Tanios, R., Haghighiabyaneh, M., Axelrod, J. L., DeStefano, J., et al. (2020) · PLoS Genetics · doi:10.1371/journal.pgen.1008558 · Cited by 57
Melatonin is a potential inhibitor of ovarian cancer: molecular aspects
Zare, H., Shafabakhsh, R., Reiter, R. J., & Asemi, Z. (2019) · Journal of Ovarian Research · doi:10.1186/s13048-019-0502-8 · Cited by 51
Alpha-Hederin, the Active Saponin of Nigella sativa, as an Anticancer Agent Inducing Apoptosis in the SKOV-3 Cell Line
Adamska, A., Stefanowicz‐Hajduk, J., & Ochocka, J. R. (2019) · Molecules · doi:10.3390/molecules24162958 · Cited by 50
Characteristics of in Vivo Model Systems for Ovarian Cancer Studies
Tudrej, P., Kujawa, K. A., Cortez, A. J., & Lisowska, K. M. (2019) · Diagnostics · doi:10.3390/diagnostics9030120 · Cited by 46
Simvastatin interferes with cancer ‘stem-cell’ plasticity reducing metastasis in ovarian cancer
Kato, S., Liberona, M., Cerda‐Infante, J., Sánchez, M., Henríquez, J., Bizama, C., Bravo, M. L. G., González, P., Gejman, R., Brañes, J. A., et al. (2018) · Endocrine Related Cancer · doi:10.1530/erc-18-0132 · Cited by 44
Extracellular matrix in high-grade serous ovarian cancer: Advances in understanding of carcinogenesis and cancer biology
Brown, Y., Hua, S., & Tanwar, P. S. (2023) · Matrix Biology · doi:10.1016/j.matbio.2023.02.004 · Cited by 47
Preclinical models of epithelial ovarian cancer: practical considerations and challenges for a meaningful application
Ciucci, A., Buttarelli, M., Fagotti, A., Scambia, G., & Gallo, D. (2022) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-022-04395-y · Cited by 44
The hedgehog pathway regulates cancer stem cells in serous adenocarcinoma of the ovary
Sneha, S., Nagare, R. P., Sidhanth, C., Krishnapriya, S., Garg, M., Ramachandran, B., Murhekar, K. M., Sundersingh, S., & Ganesan, T. S. (2020) · Cellular Oncology · doi:10.1007/s13402-020-00504-w · Cited by 40
Mouse models of epithelial ovarian cancer for preclinical studies
Karakashev, S. V., & Zhang, R. (2021) · 动物学研究 · doi:10.24272/j.issn.2095-8137.2020.382 · Cited by 42
Long non-coding RNA H19 mediates ovarian cancer cell cisplatin-resistance and migration during EMT.
Wu, Y., Zhou, Y., He, J., Sun, H., & Jin, Z. (2019) · Europe PMC (PubMed Central) · Cited by 35
A Novel Role for NUAK1 in Promoting Ovarian Cancer Metastasis through Regulation of Fibronectin Production in Spheroids
Fritz, J. L., Collins, O. M., Saxena, P., Buensuceso, A. V., Valdés, Y. R., Francis, K. E., Brown, K. R., Larsen, B. G., Colwill, K., Gingras, A., et al. (2020) · Cancers · doi:10.3390/cancers12051250 · Cited by 35
Nanotechnology-Based Cisplatin Intracellular Delivery to Enhance Chemo-Sensitivity of Ovarian Cancer
Bortot, B., Mongiat, M., Valencic, E., Monego, S. D., Licastro, D., Crosera, M., Adami, G., Rampazzo, E., Ricci, G., Romano, F., et al. (2020) · International Journal of Nanomedicine · doi:10.2147/ijn.s247114 · Cited by 33
STON2 negatively modulates stem-like properties in ovarian cancer cells via DNMT1/MUC1 pathway
Xu, S., Yue, Y., Zhang, S., Zhou, C., Cheng, X., Xie, X., Wang, X., & Lü, W. (2018) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-018-0977-y · Cited by 33
Evaluating Targeted Therapies in Ovarian Cancer Metabolism: Novel Role for PCSK9 and Second Generation mTOR Inhibitors
Sanz, D. J., Raivola, J., Karvonen, H., Arjama, M., Barker, H. R., Murumägi, A., & Ungureanu, D. (2021) · Cancers · doi:10.3390/cancers13153727 · Cited by 30
Ovarian Cancer Risk Variants Are Enriched in Histotype-Specific Enhancers and Disrupt Transcription Factor Binding Sites
Jones, M. R., Peng, P.-C., Coetzee, S. G., Tyrer, J. P., Reyes, A. L. P., Corona, R. I., Davis, B. D., Chen, S., Dezem, F. S., Seo, J.-H., et al. (2020) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2020.08.021 · Cited by 25
Harnessing preclinical models for the interrogation of ovarian cancer
Qin, T., Fan, J., Lu, F., Zhang, L., Liu, C., Xiong, Q., Zhao, Y., Chen, G., & Sun, C. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02486-z · Cited by 30
Mitochondrial membrane depolarization enhances TRAIL-induced cell death in adult human granulosa tumor cells, KGN, through inhibition of BIRC5
MacDonald, J. A., Kura, N., Sussman, C., & Woods, D. C. (2018) · Journal of Ovarian Research · doi:10.1186/s13048-018-0463-3 · Cited by 26
Integrative multi-omics analyses to identify the genetic and functional mechanisms underlying ovarian cancer risk regions
Dareng, E., Coetzee, S. G., Tyrer, J. P., Peng, P.-C., Rosenow, W. T., Chen, S., Davis, B. D., Dezem, F. S., Seo, J.-H., Nameki, R. A., et al. (2024) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2024.04.011 · Cited by 25
The Profile of MicroRNA Expression and Potential Role in the Regulation of Drug-Resistant Genes in Cisplatin- and Paclitaxel-Resistant Ovarian Cancer Cell Lines
Kaźmierczak, D., Jopek, K., Sterzyńska, K., Nowicki, M. O., Ruciński, M., & Januchowski, R. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23010526 · Cited by 25
Anti‐HER2 Super Stealth Immunoliposomes for Targeted‐Chemotherapy
Canato, E., Grigoletto, A., Zanotto, I., Tedeschini, T., Campara, B., Quaglio, G., Toffoli, G., Mandracchia, D., Dinarello, A., Tiso, N., et al. (2023) · Advanced Healthcare Materials · doi:10.1002/adhm.202301650 · Cited by 24
SIO: A Spatioimageomics Pipeline to Identify Prognostic Biomarkers Associated with the Ovarian Tumor Microenvironment
Zhu, Y., Borgogno, S. F., Sheng, J., Yeung, T.-L., Burks, J. K., Cappello, P., Jazaeri, A. A., Kim, J., Han, G. H., Birrer, M. J., et al. (2021) · Cancers · doi:10.3390/cancers13081777 · Cited by 26
Oncolytic activity of HF10 in head and neck squamous cell carcinomas
Esaki, S., Goshima, F., Ozaki, H., Takano, G., Hatano, Y., Kawakita, D., Ijichi, K., Watanabe, T., Sato, Y., Murata, T., et al. (2019) · Cancer Gene Therapy · doi:10.1038/s41417-019-0129-3 · Cited by 23
Identification of ovarian high-grade serous carcinoma cell lines that show estrogen-sensitive growth as xenografts in immunocompromised mice
Brandon, A. D. H., Box, G., Hallsworth, A., Court, W. J., Matthews, N., Herodek, B., Bermejo-Arteagabeitia, A., Valenti, M. R., & Kirkin, V. (2020) · Scientific Reports · doi:10.1038/s41598-020-67533-1 · Cited by 23
Evaluation of mitochondrial biogenesis and ROS generation in high-grade serous ovarian cancer
Koc, Z. C., Sollars, V. E., Zgheib, N. B., Rankin, G. O., & Koc, E. C. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1129352 · Cited by 22
Fusogenic peptide delivery of bioactive siRNAs targeting CSNK2A1 for treatment of ovarian cancer
Samec, T., Alatise, K. L., Boulos, J., Gilmore, S. N., Hazelton, A., Coffin, C., & Alexander-Bryant, A. A. (2022) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2022.09.012 · Cited by 21
Omental Preadipocytes Stimulate Matrix Remodeling and IGF Signaling to Support Ovarian Cancer Metastasis
Waters, J. A., Robinson, M., Lujano-Olazaba, O., Lucht, C., Gilbert, S. F., & House, C. D. (2024) · Cancer Research · doi:10.1158/0008-5472.can-23-2613 · Cited by 20
Self-citation
Reduced expression of enolase-1 correlates with high intracellular glucose levels and increased senescence in cisplatin-resistant ovarian cancer cells.
Santana‐Rivera, Y., Rabelo-Fernández, R. J., Quiñones‐Díaz, B. I., Grafals‐Ruiz, N., Santiago-Sánchez, G. S., Lozada-Delgado, E. L., Echevarría-Vargas, I. M., Apiz, J., Soto, D., Rosado, A., et al. (2020) · PubMed Central · Cited by 20
Modelling Epithelial Ovarian Cancer in Mice: Classical and Emerging Approaches
Zakarya, R., Howell, V. M., & Colvin, E. K. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21134806 · Cited by 24
TWEAK–Fn14–RelB Signaling Cascade Promotes Stem Cell–like Features that Contribute to Post-Chemotherapy Ovarian Cancer Relapse
Holmberg, R., Robinson, M., Gilbert, S. F., Lujano-Olazaba, O., Waters, J. A., Kogan, E., Velasquez, C. L. R., Stevenson, D., Cruz, L. S., Alexander, L. J., et al. (2022) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-22-0486 · Cited by 21
Self-citation
Four and a Half LIM Domains 2 (FHL2) Contribute to the Epithelial Ovarian Cancer Carcinogenesis
Wang, C., Lv, X., He, C., Davis, J. S., Wang, C., & Hua, G. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21207751 · Cited by 19
Chondroitin sulfate proteoglycan 4, a targetable oncoantigen that promotes ovarian cancer growth, invasion, cisplatin resistance and spheroid formation
Yang, J., Liao, Q., Price, M., Moriarity, B. S., Wolf, N. K., Felices, M., Miller, J. S., Geller, M. A., Bendzick, L. E., Hopps, R., et al. (2021) · Translational Oncology · doi:10.1016/j.tranon.2021.101318 · Cited by 18
Dexamethasone potentiates chimeric antigen receptor T cell persistence and function by enhancing IL-7Rα expression
Munoz, A., Urak, R. Z., Taus, E., Hsieh, H.-J., Awuah, D., Vyas, V., Lim, L., Jin, K., Lin, S., Priceman, S. J., et al. (2023) · Molecular Therapy · doi:10.1016/j.ymthe.2023.12.017 · Cited by 18
The role of Piezo1 mechanotransduction in high-grade serous ovarian cancer: Insights from an in vitro model of collective detachment
Micek, H. M., Yang, N., Dutta, M., Rosenstock, L., Ma, Y., Hielsberg, C., McCord, M., Notbohm, J., McGregor, S. M., & Kreeger, P. K. (2024) · Science Advances · doi:10.1126/sciadv.adl4463 · Cited by 17
Withaferin A and Ovarian Cancer Antagonistically Regulate Skeletal Muscle Mass
Straughn, A. R., Kelm, N. Q., & Kakar, S. S. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.636498 · Cited by 18
UGDH promotes tumor-initiating cells and a fibroinflammatory tumor microenvironment in ovarian cancer
Harrington, B. S., Kamdar, R. D., Ning, F., Korrapati, S., Caminear, M. W., Hernandez, L. F., Butcher, D. O., Edmondson, E. F., Traficante, N., Australian Ovarian Cancer Study Group, et al. (2023) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-023-02820-z · Cited by 16
Self-citation
6-Plex mdSUGAR Isobaric-Labeling Guide Fingerprint Embedding for Glycomics Analysis
Ma, M., Li, M., Zhu, Y., Zhao, Y., Wu, F., Wang, Z., Yu, F., Chiang, H.-Y., Patankar, M. S., Chang, C., et al. (2023) · Analytical Chemistry · doi:10.1021/acs.analchem.3c03342 · Cited by 16
A Systematic Comparative Assessment of the Response of Ovarian Cancer Cells to the Chemotherapeutic Cisplatin in 3D Models of Various Structural and Biochemical Configurations—Does One Model Type Fit All?
Gupta, P., Miller, A. F., Olayanju, A., Madhuri, T. K., & Velliou, E. G. (2022) · Cancers · doi:10.3390/cancers14051274 · Cited by 18
FAP is critical for ovarian cancer cell survival by sustaining NF-κB activation through recruitment of PRKDC in lipid rafts
Li, B., Ding, Z., Calbay, O., Li, Y., Li, T., Jin, L., & Huang, S. (2022) · Cancer Gene Therapy · doi:10.1038/s41417-022-00575-x · Cited by 17
ONC201 induces the unfolded protein response (UPR) in high‐ and low‐grade ovarian carcinoma cell lines and leads to cell death regardless of platinum sensitivity
Rumman, M., Buck, S. A., Polin, L., Dzinic, S. H., Boerner, J. L., & Winer, I. S. (2021) · Cancer Medicine · doi:10.1002/cam4.3858 · Cited by 14
Use of Transabdominal Ultrasound for the detection of intra-peritoneal tumor engraftment and growth in mouse xenografts of epithelial ovarian cancer
Chambers, L., Esakov, E. L., Braley, C., AlHilli, M. M., Michener, C. M., & Reizes, O. (2020) · PLoS ONE · doi:10.1371/journal.pone.0228511 · Cited by 14
Melatonin Sensitizes OVCAR-3 Cells to Cisplatin through Suppression of PI3K/Akt Pathway
Baghal-Sadriforoush, S., Bagheri, M., Rad, I. A., & Sotoodehnejadnematalahi, F. (2022) · Cellular and Molecular Biology · doi:10.14715/cmb/2022.68.4.19 · Cited by 14
Novel Therapeutics for Ovarian Cancer: The 11th Biennial Rivkin Center Ovarian Cancer Research Symposium
Johnson, N., & Liao, J. B. (2017) · International Journal of Gynecological Cancer · doi:10.1097/igc.0000000000001115 · Cited by 12
Smac-mimetic enhances antitumor effect of standard chemotherapy in ovarian cancer models via Caspase 8-independent mechanism
Hernandez, L. F., Dull, A. B., Korrapati, S., & Annunziata, C. M. (2021) · Cell Death Discovery · doi:10.1038/s41420-021-00511-2 · Cited by 12
Self-citation
GBA inhibition suppresses ovarian cancer growth, survival and receptor tyrosine kinase AXL-mediated signaling pathways
Wang, G., Ouyang, B., Jing, F., & Dai, X. (2022) · Korean Journal of Physiology and Pharmacology · doi:10.4196/kjpp.2023.27.1.21 · Cited by 11
Mechanomimetic 3D Scaffolds as a Humanized In Vitro Model for Ovarian Cancer
Paradiso, F., Lenna, S., Gazze, S. A., García-Parra, J., Murphy, K., Margarit, L., González, D., Francis, L. W., & Taraballi, F. (2022) · Cells · doi:10.3390/cells11050824 · Cited by 11
In vivo selection reveals autophagy promotes adaptation of metastatic ovarian cancer cells to abdominal microenvironment
Kuo, C.-L., Jiang, Z., Wang, Y., Lin, T., Huang, W., Wu, F., & Luo, C. (2019) · Cancer Science · doi:10.1111/cas.14162 · Cited by 11
The significance of interferon gamma inducible protein 16 (IFI16) expression in drug resistant ovarian cancer cell lines
Borucka, J., Sterzyńska, K., Kaźmierczak, D., Świerczewska, M., Nowacka, M., Wojtowicz, K., Klejewski, A., Nowicki, M. O., Zabel, M., Ramlau, R., et al. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113036 · Cited by 10
A Cell-Autonomous Oncosuppressive Role of Human RNASET2 Affecting ECM-Mediated Oncogenic Signaling
Roggiani, F., Riva, C., Raspagliesi, F., Porta, G., Valli, R., Taramelli, R., Acquati, F., Mezzanzanica, D., & Tomassetti, A. (2019) · Cancers · doi:10.3390/cancers11020255 · Cited by 10
Identifying cell lines across pan-cancer to be used in preclinical research as a proxy for patient tumor samples
Bose, B., & Bozdag, S. (2024) · Communications Biology · doi:10.1038/s42003-024-06812-3 · Cited by 10
Three-Dimensional Model Analysis Revealed Differential Cytotoxic Effects of the NK-92 Cell Line and Primary NK Cells on Breast and Ovarian Carcinoma Cell Lines Mediated by Variations in Receptor–Ligand Interactions and Soluble Factor Profiles
Alekseeva, N. A., Boyko, A. A., Shevchenko, M. A., Grechikhina, M. V., Streltsova, M. A., Alekseeva, L. G., Sapozhnikov, A. M., Deyev, S. M., & Kovalenko, E. I. (2024) · Biomedicines · doi:10.3390/biomedicines12102398 · Cited by 10
Distinct effects of sacituzumab govitecan and berzosertib on DNA damage response in ovarian cancer
Nair, J. R., Huang, T., Sunkara, A. D., Pruitt, M. R., Ibanez, K. R., Chiang, C.-Y., Cheng, K. C.-C., Wilson, K. M., Cardillo, T. M., Hofsess, S. J., et al. (2024) · iScience · doi:10.1016/j.isci.2024.111283 · Cited by 9
Targeting Microtubule-Associated Protein Tau in Chemotherapy-Resistant Models of High-Grade Serous Ovarian Carcinoma
Barbolina, M. V. (2022) · Cancers · doi:10.3390/cancers14184535 · Cited by 9
The overexpression of actin related protein 2/3 complex subunit 1B(ARPC1B) promotes the ovarian cancer progression via activation of the Wnt/β-catenin signaling pathway
Huang, J., Zhou, H., Tan, C., Mo, S., Liu, T., & Kuang, Y. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1182677 · Cited by 9
Molecular imaging-monitored radiofrequency hyperthermia-enhanced intratumoral herpes simplex virus-thymidine kinase gene therapy for rat orthotopic ovarian cancer
Li, Y., Zhao, S., Zhang, F., Jin, G., Zhou, Y., Li, P., Shin, D. S., & Yang, X. (2020) · International Journal of Hyperthermia · doi:10.1080/02656736.2020.1711973 · Cited by 9
The protease ADAMTS 5 controls ovarian cancer cell invasion, downstream of Rab25
Yuan, S., Bacchetti, R., Adams, J., Cuffaro, D., Rossello, A., Nuti, E., Santamaria, S., & Rainero, E. (2025) · FEBS Journal · doi:10.1111/febs.70080 · Cited by 8
Novel chromobox 2 inhibitory peptide decreases tumor progression
Brubaker, L. W., Backos, D. S., Nguyen, V., Reigan, P., Yamamoto, T. M., Woodruff, E. R., Iwanaga, R., Wempe, M. F., Kumar, V., Persenaire, C., et al. (2023) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2023.2218614 · Cited by 8
Revolutionizing ovarian cancer therapy by drug repositioning for accelerated and cost-effective treatments
Villegas‐Vázquez, E. Y., Marín-Carrasco, F. P., Reyes‐Hernández, O. D., Báez-González, A. S., Bustamante-Montes, L. P., Padilla‐Benavides, T., Granados, L. I. Q., & Figueroa‐González, G. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2024.1514120 · Cited by 8
Deciphering the ghost proteome in ovarian cancer cells by deep proteogenomic characterization
Garcia-del Rio, D. F., Derhourhi, M., Bonnefond, A., Leblanc, S., Guilloy, N., Roucou, X., Eyckerman, S., Gevaert, K., Salzet, M., & Cardon, T. (2024) · Cell Death & Disease · doi:10.1038/s41419-024-07046-1 · Cited by 7
Targeting ATP Synthase by Bedaquiline as a Therapeutic Strategy to Sensitize Ovarian Cancer to Cisplatin
Zhu, H., Chen, Q., Zhao, L., & Hu, P. (2023) · Nutrition and Cancer · doi:10.1080/01635581.2023.2180825 · Cited by 7
Targeting estrogen metabolism in high-grade serous ovarian cancer shows promise to overcome platinum resistance
Marolt, N., Pavlič, R., Kreft, T., Gjorgoska, M., & Rižner, T. L. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.117069 · Cited by 7
Attenuated miR-203b-3p is critical for ovarian cancer progression and aptamer/miR-203b-3p chimera can be explored as a therapeutic
Li, T., Li, Y., Rehmani, H., Guo, J., Padia, R. N., Calbay, O., Ding, Z., Jiang, Y., Jin, L., & Huang, S. (2022) · Advances in Cancer Biology - Metastasis · doi:10.1016/j.adcanc.2022.100031 · Cited by 7
Targeting metabolic vulnerability by combining NAMPT inhibitors and disulfiram for treatment of recurrent ovarian cancer
Kudo, K., Greer, Y. E., Crooks, D. R., Yang, Y., Brender, J., Yoshida, T., Harrington, B. S., Kamdar, R. D., Korrapati, S., Shibuya, Y., et al. (2025) · Cell Death and Disease · doi:10.1038/s41419-025-07672-3 · Cited by 7
Self-citation
VERU-111, an orally available tubulin inhibitor, suppresses ovarian tumor growth and metastasis
Waddell, S., Zhao, G., Liu, Z., Chen, H., Zhang, W., Wang, Y., Miller, D. D., Yue, J., & Li, W. (2024) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.124.002298 · Cited by 6
Evaluation of effects of bisphenol analogs AF, S, and F on viability, proliferation, production of selected cancer-related factors, and expression of selected transcripts in Caov-3 human ovarian epithelial cell line
Mlynarčíková, A. B., & Scsuková, S. (2024) · Food and Chemical Toxicology · doi:10.1016/j.fct.2024.114889 · Cited by 6
Development of a Bioluminescent BRCA1-Deficient Xenograft Model of Disseminated, High-Grade Serous Ovarian Cancer
Shen, Y. T., Wang, L. L., Evans, J. C., Allen, C. J., & Piquette‐Miller, M. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20102498 · Cited by 6
Investigation of Physiological Effects Induced by Dehydroepiandrosterone in Human Endothelial Cells and Ovarian Cancer Cell Line
Gündoğan, G. İ., Kığ, C., Karacan, M., & Doğruman, H. (2020) · Turkish Journal of Pharmaceutical Sciences · doi:10.4274/tjps.galenos.2020.58827 · Cited by 6
UBP43 promotes epithelial ovarian carcinogenesis via activation of β‐catenin signaling pathway
Xie, H., Chen, J., Ma, C., Zhao, J., & Cui, M. (2023) · Cell Biology International · doi:10.1002/cbin.12028 · Cited by 6
Spheroid architecture strongly enhances miR-221/222 expression and promotes oxidative phosphorylation in an ovarian cancer cell line through a mechanism that includes restriction of miR-9 expression
Ward, A. S., Hall, C. N., Tree, M. O., & Kohtz, D. S. (2024) · Molecular Biology Reports · doi:10.1007/s11033-023-09168-9 · Cited by 6
The TGFBI gene and protein expression in topotecan resistant ovarian cancer cell lines
Wojtowicz, K., Świerczewska, M., Nowicki, M. O., & Januchowski, R. (2023) · Advances in Medical Sciences · doi:10.1016/j.advms.2023.09.013 · Cited by 4
Effect of overexpression of Rac1 on radiosensitivity of nasopharyngeal carcinoma xenografts in nude mice, and the underlying mechanism
Liao, K., Zheng, R., Feng, J., Liu, H., & Xie, G. (2023) · Tropical Journal of Pharmaceutical Research · doi:10.4314/tjpr.v22i4.11 · Cited by 4
A Novel Role of Connective Tissue Growth Factor in the Regulation of the Epithelial Phenotype
Gogoi, R. P., Galoforo, S., Fox, A. L., Morris, C., Ramos, H., Gogoi, V., Chehade, H., Adzibolosu, N. K., Shi, C., Zhang, J., et al. (2023) · Cancers · doi:10.3390/cancers15194834 · Cited by 5
CTDPathSim
Bose, B., & Bozdag, S. (2020) · ACM International Conference on Bioinformatics, Computational Biology, and Health Informatics (ACM-BCB) · doi:10.1145/3388440.3412456 · Cited by 2
Exploring the role of estrogens and steroid sulfatase inhibition in platinum resistance, proliferation, migration, and cell death in high-grade serous ovarian cancer cells
Marolt, N., Potter, B. V. L., & Rižner, T. L. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118278 · Cited by 2
Revealing genetic drivers of ovarian cancer and chemoresistance: insights from whole-genome CRISPR-knockout library screens
Skipper, T. S., Dickson, K.-A., Denes, C. E., Waller, M. A., D'Araujo, T. Y., Neely, G. G., Bowden, N. A., Faiz, A., & Marsh, D. J. (2025) · Cellular Oncology · doi:10.1007/s13402-025-01102-4 · Cited by 2
Prolyl-isomerase Pin1 drives platinum resistance by regulating Notch3 stability and function in ovarian cancer
Giuli, M. V., Mancusi, A., Natiello, B., Cristofano, S. D., Reali, R., Pignataro, M. G., D’Andrea, D., Magno, L. D., Nicoletti, C., Giorgi, A., et al. (2026) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-026-03658-x · Cited by 2
Circ-RNF111 Promotes Proliferation of Ovarian Cancer Cell SKOV-3 by Targeting the MiR-556-5p/CCND1 Axis
Zuo, L., Tan, Y., Xu, Q., Li, X., & Mi, X. (2024) · Biochemical Genetics · doi:10.1007/s10528-024-10665-0 · Cited by 2
The significance of HERC5, IFIH1, SAMD4, SEMA3A and MCTP1 genes expression in resistance to cytotoxic drugs in ovarian cancer cell lines
Nowacka, M., Ginter-Matuszewska, B., Świerczewska, M., Nowicki, M. O., Zabel, M., Sterzyńska, K., & Januchowski, R. (2021) · Medical Journal of Cell Biology · doi:10.2478/acb-2021-0019 · Cited by 2
Cancer Study: Cell to the Animal Models
Amălinei, C., Grigoraş, A., Pricope, D. L., & Pricop, B.-I. (2023) · Handbook of Animal Models and its Uses in Cancer Research · doi:10.1007/978-981-19-3824-5_2 · Cited by 2
Deep learning on image-omics data in identifying prognostic immune biomarkers for ovarian cancerPreprint
Zhu, Y., Borgogno, S. F., Sheng, J., Yeung, T.-L., Burks, J. K., Cappello, P., Jazaeri, A. A., Kim, J., Han, G. H., Birrer, M., et al. (2020) · Research Square · doi:10.21203/rs.3.rs-67036/v1 · Cited by 2
Models of High-Grade Serous Ovarian CarcinomaPreprint
Pundel, O. J., & Neel, B. G. (2025) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a041949 · Cited by 2
Bioimpedance Spectroscopy for Noninvasive Monitoring of Tumor Spheroids
Khattab, A., Grabowski, R., Oenning, L., Schmees, C., & Zeck, G. M. (2024) · International Workshop on Impedance Spectroscopy (IWIS) · doi:10.1109/iwis63047.2024.10847237 · Cited by 1
Orientation of Preclinical Research in Ovarian Cancer
Baert, T., Garg, A. D., Agostinis, P., Vergote, I. B., & Coosemans, A. (2017) · International Journal of Gynecological Cancer · doi:10.1097/igc.0000000000001053 · Cited by 1
Dual Targeting of Mitochondrial Membrane Potential and XIAP by Mebendazole Triggers Apoptosis in Ovarian Cancer Cells: An Integrated In Vitro and In Silico Perspective
Gupta, R. K. (2025) · DNA and cell biology reports. · doi:10.1177/29979811251379351 · Cited by 1
Investigating different type of ovary cancer cell line for NK cell in vitro co-culture cytotoxic assay
Pangjaya, L. F., Khaerunnisa, S., Mazfufah, N. F., Budiman, R. L., & Antarianto, R. D. (2021) · AIP conference proceedings · doi:10.1063/5.0049155 · Cited by 1
Finding the best cell lines across pan-cancer to use in pre-clinical research as a proxy for patient tumor samples considering immune cells, multi-omics, and cancer pathwaysPreprint
Bose, B., & Bozdag, S. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.12.18.520831 · Cited by 1
CTDPathSim: Cell line-tumor deconvoluted pathway-based similarity in the context of precision medicine in cancer *Preprint
Bose, B., & Bozdag, S. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.06.13.149666
Models of ovarian cancer to test new agents
Sodi, V. L., Craig, A. D., Peri, S., & Connolly, D. C. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-819840-7.00012-1
Melatonin Sensitize the Ovarian Cancer Cells to Cisplatin through suppression of PI3K/Akt pathwayPreprint
Baghal-Sadriforoush, S., Bagheri, M., Rad, I. A., & Sotoodehnejadnematalahi, F. (2021) · Research Square · doi:10.21203/rs.3.rs-497936/v1

Authors: Hernandez, L., Kim, M. K., Lyle, L. T., Bunch, K. P., House, C. D., Ning, F., Noonan, A. M., & Annunziata, C. M.
Affiliations: National Cancer Institute (US)
Corresponding author: Annunziata, Christina M.
ORCID: Lyle, L. Tiffany
Bunch, Kristen P.
House, Carrie D.
Ning, Franklin
Noonan, Anne M.
Annunziata, Christina M.
Venue: Gynecologic Oncology
Publisher: Elsevier BV
Published: 2016-08
Volume: 142
Issue: 2
Pages: 332-340
ISSN: 0090-8258 (ISSN-L)
DOI: 10.1016/j.ygyno.2016.05.028
PMC: PMC4961516
OpenAlex: W2399911066
Cited by: 121
References: 43
Citations by year: 2026: 10 · 2025: 10 · 2024: 15 · 2023: 16 · 2022: 17 · 2021: 15 · 2020: 17 · 2019: 14 · 2018: 4 · 2017: 3
FWCI: 9.30
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: Gynecologic Oncology (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Funders: National Cancer Institute Intramural Research Program (ZIA BC 011054)
Topics: Health Sciences › Medicine › Oncology › Ovarian cancer diagnosis and treatment
Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
Health Sciences › Medicine › Reproductive Medicine › Reproductive Biology and Fertility
Keywords: ovarian cancer cell lines, in vivo tumorigenicity, xenograft models, nude mice, subcutaneous implantation, intraperitoneal implantation, gene expression profiling, proteomic profiling, preclinical model selection
MeSH terms: Animals, Drug Screening Assays, Antitumor, Female, Humans, Neoplasm Transplantation, Ovarian Neoplasms, Xenograft Model Antitumor Assays, Cell Line, Tumor, Mice, Heterografts

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Characterization of ovarian cancer cell lines as in vivo models for preclinical studies

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks